ACCD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACCD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Accolade's Total Stockholders Equity for the quarter that ended in Feb. 2024 was $445.5 Mil. Accolade's Total Assets for the quarter that ended in Feb. 2024 was $788.2 Mil. Therefore, Accolade's Equity to Asset Ratio for the quarter that ended in Feb. 2024 was 0.57.
The historical rank and industry rank for Accolade's Equity-to-Asset or its related term are showing as below:
During the past 7 years, the highest Equity to Asset Ratio of Accolade was 0.82. The lowest was -3.90. And the median was 0.53.
The historical data trend for Accolade's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accolade Annual Data | ||||||||||||||||
Trend | Feb18 | Feb19 | Feb20 | Feb21 | Feb22 | Feb23 | Feb24 | |||||||||
Equity-to-Asset | Get a 7-Day Free Trial | -3.51 | 0.82 | 0.67 | 0.53 | 0.57 |
Accolade Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Equity-to-Asset | Get a 7-Day Free Trial | 0.53 | 0.52 | 0.51 | 0.55 | 0.57 |
For the Health Information Services subindustry, Accolade's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Accolade's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Accolade's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Accolade's Equity to Asset Ratio for the fiscal year that ended in Feb. 2024 is calculated as
Equity to Asset (A: Feb. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 445.465 | / | 788.151 | |
= | 0.57 |
Accolade's Equity to Asset Ratio for the quarter that ended in Feb. 2024 is calculated as
Equity to Asset (Q: Feb. 2024 ) | = | Total Stockholders Equity | / | Total Assets |
= | 445.465 | / | 788.151 | |
= | 0.57 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accolade (NAS:ACCD) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Thank you for viewing the detailed overview of Accolade's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Richard Eskew | officer: EVP General Counsel | C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462 |
Stephen H. Barnes | officer: Chief Financial Officer | C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462 |
Rajeev Singh | director, officer: Chief Executive Officer | 6222 185TH AVENUE NE, REDMOND WA 98052 |
Robert N Cavanaugh | officer: President | 1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404 |
Mchugh Colin | officer: Chief Accounting Officer | C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462 |
Michael W Hilton | officer: Chief Product Officer | 6222 185TH AVE, REDMOND WA 98052 |
Peter S Klein | director | C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399 |
Cindy Kent | director | 7601 PENN AVENUE SOUTH, RICHFIELD MN 55418 |
Patricia L Wadors | director | C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050 |
Dawn G Lepore | director | 1425 BROADWAY PMB 41, SEATTLE WA 99122 |
Jeffrey D Jordan | director | 2865 SAND HILL ROAD #101, MENLO PARK CA 94025 |
Elizabeth G Nabel | director | BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115 |
Jeffrey S Brodsky | director | C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036 |
Thomas J Neff | director | SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172 |
William H. Frist | director | 600 MONTGOMERY STREET, SAN FRANCISCO CA 94111 |
From GuruFocus
By PRNewswire • 10-09-2023
By PRNewswire PRNewswire • 06-05-2023
By GuruFocus Research • 01-08-2024
By GuruFocus Research GuruFocus Editor • 05-25-2023
By GuruFocus Research • 05-28-2023
By GuruFocus Research • 09-14-2023
By GuruFocus Research • 05-27-2023
By GuruFocus Research GuruFocus Editor • 05-25-2023
By Marketwired • 06-29-2023
By GuruFocus Research • 05-28-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.